USC Norris | Strategic Alliance Partners

Latest from USC Norris


Dr. El-Khoueiry on Immunotherapy Combinations in HCC

July 26, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC

July 19, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19, 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRC

June 12, 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

June 12, 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

USC Norris Launches Diversity-Driven Study Among Clinical Trial Participants

April 29, 2019

USC Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities.

Dr. Quinn on Current State of Biomarkers in RCC

April 19, 2019

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.